289 related articles for article (PubMed ID: 34744712)
1. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring and
Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
4. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study.
Zhou L; Li M; Li H; Guo Z; Gao Y; Zhang H; Qin F; Sang Z; Xing Q; Cheng L; Cao W
Front Cell Infect Microbiol; 2023; 13():1157944. PubMed ID: 37565064
[TBL] [Abstract][Full Text] [Related]
7. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.
Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
10. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
[TBL] [Abstract][Full Text] [Related]
13. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.
Resztak M; Sobiak J; Czyrski A
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959272
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.
Moriyama B; Kadri S; Henning SA; Danner RL; Walsh TJ; Penzak SR
Curr Fungal Infect Rep; 2015 Jun; 9(2):74-87. PubMed ID: 26918067
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
[TBL] [Abstract][Full Text] [Related]
17. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
[TBL] [Abstract][Full Text] [Related]
18. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
Sienkiewicz B; Urbaniak-Kujda D; Dybko J; Dryś A; Hurkacz M; Wróbel T; Wiela-Hojeńska A
Pathol Oncol Res; 2018 Jul; 24(3):541-545. PubMed ID: 28685218
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
